Table of Contents
Cell therapies are growing in variety and effectiveness across many diseases. In the fight against Duchenne muscular dystrophy, deramiocel has emerged as an effective treatment for patients in early clinical trials, and now new data from the deramiocel DMD Phase III trial extend that efficacy to patients with advanced disease.
What the Deramiocel DMD Phase III Trial Found
New data from the HOPE-3 Phase III clinical trial, published in The Lancet, expand deramiocel’s demonstrated efficacy to include patients with advanced disease. “Deramiocel, a heart-derived cellular therapy consisting of human allogeneic cardiosphere-derived cells, improved cardiac and skeletal muscle function in Phase I-II studies of DMD,” the study authors wrote. “Our aim was to assess the efficacy and safety of deramiocel in advanced DMD and support the findings of HOPE-2.”
A Disease With No Cure
Duchenne muscular dystrophy is an X-linked genetic disease that causes muscles, including the heart, to gradually weaken and waste away. Affecting almost exclusively boys and young men, most patients lose the ability to walk as the disease progresses and come to depend on their arms and hands for everyday tasks and independence. There is no cure.
How the Deramiocel DMD Phase III Trial Was Designed
In the HOPE-3 trial, 106 male participants aged 10 to 22 with advanced DMD were randomly assigned treatment with deramiocel, 54 participants, or placebo, 52 participants. The treatment was delivered intravenously every three months at 20 outpatient trial sites across the U.S. Patients were monitored over 12 months for skeletal muscle function, by determining the mean percentage change from baseline for full upper limb function, and cardiac function via left ventricular ejection fraction.
The Trial’s Historic Significance
This report is the first Phase III trial of a cell therapy made from donor cells and administered through the bloodstream to treat a genetic disease, and the first such trial in boys and young men whose disease is already advanced.
Key Results From the Deramiocel DMD Phase III Trial
Patients treated with deramiocel showed significantly less decline in upper limb function, a critical measure of independence that affects activities such as feeding, grooming and using technology, achieving a 54% reduction in the mean progression of skeletal muscle disease over 12 months.
Cardiac Benefits Also Observed
The treatment also demonstrated advantages on measures of cardiac function and disease-related heart scarring, two major causes of illness and premature death in this condition, with a 91% to 119% slowing of average cardiac decline reported across different measures, according to separate reporting on the trial, representing a stabilization of cardiomyopathy progression not typically seen with other cardiac treatments for the disease. However, this cardiac benefit did not result in a clear difference in the heart’s overall pumping ability between the two groups.
What Researchers Are Saying About the Deramiocel DMD Phase III Trial
“What makes these findings especially meaningful is that deramiocel demonstrated effects across multiple systems impacted by Duchenne muscular dystrophy,” said Craig McDonald, chair of the Department of Physical Medicine and Rehabilitation at UC Davis Health and lead study investigator. “Preserving arm and hand function is critically important for maintaining independence and quality of life in people living with” the disease.
Addressing Prior Regulatory Concerns
The HOPE-3 trial’s results support deramiocel’s potential for regulatory approval, addressing the FDA’s previous concerns about efficacy evidence, following an earlier regulatory setback for the therapy’s developer, Capricor Therapeutics.
The Broader Landscape of DMD Therapies Beyond This Trial
This investigational cell therapy is just one example of the growing number of therapeutic modalities for DMD that span muscle-preserving biologics targeting the myostatin and activin signaling pathways, among other approaches.
A Novel Epigenetic Editing Approach
Among the most novel is Epicrispr Biotechnologies’s epigenetic editing platform, which is advancing EPI-331 to upregulate utrophin, the natural functional analog of dystrophin, offering the potential for a one-time therapy applicable across nearly all forms of the disease, a notably different mechanism from deramiocel’s cell-based approach targeting symptoms rather than the underlying genetic deficiency.
What the Deramiocel DMD Phase III Trial Means for Patients
While advances in care have improved survival for DMD patients, there remains a critical need for therapies to address multiple aspects of the disease, particularly in non-ambulatory patients with advanced disease, a population the HOPE-3 trial specifically targeted. Given that deramiocel does not correct the underlying dystrophin deficiency but instead slows disease progression across multiple affected systems, the therapy may offer meaningful quality-of-life benefits even without addressing the disease’s root genetic cause.
What to Watch Going Forward
As deramiocel’s developer moves toward potential regulatory approval following these HOPE-3 results, patients, families, and clinicians in the DMD community will likely watch closely for how quickly the therapy could become available, particularly given the trial’s specific focus on advanced, non-ambulatory patients who have had limited treatment options to date. The deramiocel DMD Phase III trial results may also influence how other cell-based and gene-editing therapies in development, including Epicrispr’s EPI-331, position themselves within an increasingly diverse treatment landscape for this rare genetic disease.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
